Klevernic IV, Morton S, Davis RJ, Cohen P (2009) Phosphorylation of Ewing's sarcoma protein (EWS) and EWS-Fli1 in response to DNA damage. Biochem J 418, 625-34 19076070

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S345-p - Chk1 (human) ▲

Modsite: LVQGIsFsQPtCPDH SwissProt Entrez-Gene Orthologous residues Chk1 (human): S345‑p, Chk1 (mouse): S345‑p, Chk1 (rat): S345‑p, Chk1 (chicken): S345‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MMS increase KU-55933 MMS no effect upon treatment-induced increase UV increase

T68-p - Chk2 (human) ▲

Modsite: SsLEtVstQELYsIP SwissProt Entrez-Gene Orthologous residues Chk2 (human): T68‑p, Chk2 iso9 (human): T68‑p, Chk2 iso11 (human): T68‑p, Chk2 iso12 (human): T68‑p, Chk2 (mouse): T77‑p, Chk2 (rat): T76‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MMS increase KU-55933 MMS inhibit treatment-induced increase UV increase

T79-p - EWS (human) ▲

Modsite: QPPTGYTtPTAPQAY SwissProt Entrez-Gene Orthologous residues EWS (human): T79‑p, EWS iso2 (human): T79‑p, EWS iso3 (human): T79‑p, EWS iso4 (human): T79‑p, EWS iso5 (human): T85‑p, EWS (mouse): T79‑p, EWS (rat): T79‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting Disease tissue studied:  bone cancer, Ewing's sarcoma, colorectal cancer, colorectal carcinoma Relevant cell lines - cell types - tissues:  293 (epithelial), HCT116 (intestinal), RD-ES (bone cell), SK-ES-1 Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE P38A (human) KINASE ERK2 (human) KINASE JNK1 iso2 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE ATM (human) pharmacological inhibitor of upstream enzyme KINASE ERK2 (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme KINASE P38B (human) pharmacological inhibitor of upstream enzyme KINASE ERK1 (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme KINASE JNK1 iso2 (human) pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme KINASE ATR (human) pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme KINASE P38A (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase PD184352 EGF inhibit treatment-induced increase U0126 EGF inhibit treatment-induced increase phorbol_ester increase PD184352 phorbol_ester inhibit treatment-induced increase U0126 phorbol_ester inhibit treatment-induced increase MMS increase PD184352 MMS no effect upon treatment-induced increase SB203580 MMS no effect upon treatment-induced increase SB203580 MMS inhibit treatment-induced increase in RD-ES and SK-ES-1 cells BIRB-0796 MMS no effect upon treatment-induced increase 1 microM concentration BIRB-0796 MMS inhibit treatment-induced increase 10 microM concentration BIRB-0796 MMS inhibit treatment-induced increase in SK-ES-1 and RD-ES cells KU-55933 MMS inhibit treatment-induced increase UV increase

S423-p - TAB1 (human) ▲

Modsite: QMVNGAHsASTLDEA SwissProt Entrez-Gene Orthologous residues TAB1 (human): S423‑p, TAB1 iso2 (human): S423‑p, TAB1 (mouse): S421‑p, TAB1 (rat): S421‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MMS increase SB203580 MMS inhibit treatment-induced increase BIRB-0796 MMS inhibit treatment-induced increase

T79-p - EWS (mouse) ▲

Modsite: QPPTGYStPTAPQAY SwissProt Entrez-Gene Orthologous residues EWS (human): T79‑p, EWS iso2 (human): T79‑p, EWS iso3 (human): T79‑p, EWS iso4 (human): T79‑p, EWS iso5 (human): T85‑p, EWS (mouse): T79‑p, EWS (rat): T79‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human